Home › NDC Lookup › Ingredients › Erythromycin › 00093-5572-01
⚪image loading
(from DailyMed)

Erythromycin 500 mg Tablet, Film Coated, 100-count — NDC 0093-5572-01 (Billing 00093-5572-01)

by Teva Pharmaceuticals USA, Inc. · 100 TABLET, FILM COATED in 1 BOTTLE

This is a package of 100 tablets of Erythromycin 500 mg Tablet, Film Coated from Teva Pharmaceuticals USA, Inc., marketed since Feb 2021 and currently FDA-listed; retail pharmacies pay about $2.51 per tablet (NADAC).

NDC 00093-5572-01
🏷️ FDA NDC (as labeled) 0093-5572-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$2.51 NADAC Per package$251.04 / 100 tablets Pack sizes3 compare ↓
Also priced by: Part D plans $3.39/unit — full pricing hub ↓
Product page 00093-5572-56 Also comes in: 30 tablets 0093-5572-56 8565 tablets 0093-5572-99
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-5572-01 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0093 labeler · 5572 product · 01 package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0093557201 7
FDA record last changed
Oct 8, 2026
⚠️
Other active recalls for Erythromycin (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Apr 29, 2026 — CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0545-2026
Class II · Apr 29, 2026 — CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit (Zydus Pharmaceuticals (USA) Inc) · FDA recall D-0544-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-5572-01
Product NDC 0093-5572
11-digit billing NDC 00093557201
NCPDP billing unit EA — each (per item)
SPL Set ID 8cd80b69-b7f5-4779-8e6f-10c9a129449e
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2021-02-12
Dosage form TABLET, FILM COATED
Substance ERYTHROMYCIN

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 03100005000310
GPI class Erythromycin Base
GCN Seq No 009262
GCN 40721
HICL code 004022
Ingredient (HICL) Erythromycin Base
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1D
Therapeutic class — specific (HIC3) Macrolide Antibiotics
AHFS code 08:12.12.04
AHFS class Erythromycin Antibiotics
FDB label name ERYTHROMYCIN 500 MG TABLET
FDB brand name Erythromycin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 009262
  • GCN: 40721
  • GPI-14 (Medi-Span): 03100005000310
  • HICL (First Databank): 004022
  • AHFS class code: 08:12.12.04
Why two NDCs? The FDA registers this code as 0093-5572-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-5572-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ERYTHROMYCIN 500 MG TABLET Ingredient Erythromycin Base
📗 Our plain-language guide HelloPharmacist
  • It’s an antibiotic for infections caused by susceptible bacteria. By mouth, it’s used for mild to moderate upper respiratory tract infections. The IV form covers additional infecti...
  • It depends on the product. Ery-tab delayed-release tablets can be taken with or without meals, but work best on an empty stomach. Erythromycin ethylsuccinate tablets and suspension...
  • Stomach upset is the most common. That includes nausea, vomiting, belly pain, diarrhea and loss of appetite. These tend to be more likely at higher doses. Call your doctor if they...
  • Call for severe or lasting diarrhea, hives or swelling, a severe skin rash, a racing or irregular heartbeat, fainting, yellow skin or eyes, or hearing changes. These can signal ser...
📖 Read our full Erythromycin guide →
7
Nutrient depletion considerations

Erythromycin may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Erythromycin nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $2.510 $251.04 / 100 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $3.39 $338.81 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jun 2021 Jan 2024 Apr 2026 Sep 2026 $13.221 $2.510
▼ Down 81% over the last 16 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00093-5572-01 You're viewing this 100 TABLET, FILM COATED in 1 BOTTLE $2.51 / ea $251.04 2021-05-04 — Active
00093-5572-56 0093-5572-56 Main listing 30 TABLET, FILM COATED in 1 BOTTLE $2.51 / ea $75.31 2021-05-04 — Active
00093-5572-99 0093-5572-99 8565 TABLET, FILM COATED in 1 CONTAINER — — — — Active

You're viewing one of 3 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($2.51 NADAC).

This pack shows little to no recent Medicaid volume — the 30 tablets pack carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet, film coated in 1 bottle.
How does this package differ from NDC 00093-5572-56?
Both are Erythromycin 500 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 100-count one, while NDC 00093-5572-56 is the 30 tablets package.
What NDC number is used to bill for this package of Erythromycin 500 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Erythromycin 500 mgthis 00093-5572-01 Teva 100 tablets $2.510 — Availability likely —
Erythromycin 500 mg 13668-0607-01 Torrent 100 tablets $2.510 AB Availability likely —
Erythromycin 500 mg 52536-0105-03 Wilshire 30 tablets $2.510 AB Availability likely —
Erythromycin 500 mg 70710-1048-01 Zydus 100 tablets $2.510 AB Availability likely —
Erythromycin 500 mg 75834-0243-01 Nivagen 100 tablets $2.510 AB Discontinued —
Erythromycin 500 mg 24338-0104-03 Arbor 30 tablets $6.270 AB FDA listed +150%
Erythromycin 500 mg 46708-0398-30 Alembic 30 tablets — AB FDA listed —
Erythromycin 500 mg 51407-0856-30 Golden 30 tablets — AB FDA listed —
Erythromycin 500 mg 62332-0398-30 Alembic 30 tablets — AB FDA listed —
Erythromycin 500 mg 67877-0763-01 Ascend 100 tablets — AB FDA listed —
Erythromycin 500 mg 70771-1549-01 Zydus 100 tablets — AB FDA listed —
Erythromycin 500 mg 71209-0101-01 Cadila 30 tablets — AB FDA listed —
Erythromycin 500 mg 72241-0037-05 Modavar 100 tablets — AB FDA listed —
Erythromycin 500 mg 73082-0020-01 Orange 100 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2021
On the market since
Feb 2021
📍
2026
Currently FDA-listed
5 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Erythromycin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Labeler code00093
First marketedFeb 2021
Product typeDrug For Further Processing
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
30 tablets00093-5572-56 387 Rx · $57,308
100 tablets this page00093-5572-01 No Medicaid data
8565 tablets00093-5572-99 No Medicaid data
Drug total (last 4 qtrs): 387 Rx · 11,142 units · $57,308 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Erythromycin — the ingredient across all brands.

Top reported reactions

Drug Hypersensitivity4,159
Nausea1,319
Vomiting1,157
Diarrhoea1,112
Dyspnoea1,076
Fatigue1,066
Rash1,046

Age at onset

Neonate107
Infant49
Child100
Adolescent64
Adult1,399
Elderly1,168

Reporter sex

19,105 reports
Male · 30%
Female · 70%
Unknown · 0%

Serious outcomes

Hospitalization5,067
Death1,712
Life-threatening1,327
Disabling1,168
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 1,844 379
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Teva Pharmaceuticals USA, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Teva Pharmaceuticals USA, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 2 other package presentations of this same product, including 30 tablets (00093-5572-56), 8565 tablets (00093-5572-99). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00093-5571-01 · Teva 00093-5907-86 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.